Elite Pharmaceuticals, Inc. (ELTP)
- Previous Close
0.1295 - Open
0.1290 - Bid --
- Ask --
- Day's Range
0.1270 - 0.1328 - 52 Week Range
0.0300 - 0.2100 - Volume
290,097 - Avg. Volume
1,013,261 - Market Cap (intraday)
134.856M - Beta (5Y Monthly) -0.14
- PE Ratio (TTM)
6.62 - EPS (TTM)
0.0200 - Earnings Date Jun 29, 2024 - Jul 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.
www.elitepharma.com53
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ELTP
Performance Overview: ELTP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELTP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELTP
Valuation Measures
Market Cap
131.80M
Enterprise Value
133.87M
Trailing P/E
6.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.79
Price/Book (mrq)
2.84
Enterprise Value/Revenue
2.83
Enterprise Value/EBITDA
-412.48
Financial Highlights
Profitability and Income Statement
Profit Margin
32.87%
Return on Assets (ttm)
6.83%
Return on Equity (ttm)
40.62%
Revenue (ttm)
47.32M
Net Income Avi to Common (ttm)
15.55M
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.82M
Total Debt/Equity (mrq)
16.99%
Levered Free Cash Flow (ttm)
-2.5M
Company Insights: ELTP
ELTP does not have Company Insights